Literature DB >> 18836472

Cytokine-based transformation of immune surveillance into tumor-promoting inflammation.

J B Mumm1, M Oft.   

Abstract

During the last decade, it has become clear that the mammalian immune system is able to recognize and partially suppress nascent tumors. Human T cells specific to oncogenes and onco-fetal antigens are present in human cancer patients and their tumors. At the same time, molecular links between tumor-associated inflammation and tumor progression have been uncovered, providing an explanation for the long recognized epidemiological link between inflammation and cancer. The synopsis of these findings suggests a new interpretation of tumor immunity. It appears that antigen recognition or antigen-specific T-cell expansion at large is not as profoundly impaired in tumor patients as the correct polarization, the survival and the effector function of tumor-infiltrating T cells. This review will focus on pro-inflammatory cytokines likely to contribute to the deregulation of tumor-specific immunity and its consequences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836472     DOI: 10.1038/onc.2008.275

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

Review 1.  Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation.

Authors:  Sujatha Muralidharan; Pranoti Mandrekar
Journal:  J Leukoc Biol       Date:  2013-08-29       Impact factor: 4.962

Review 2.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

Review 3.  Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies.

Authors:  Kunyu Shen; David W Johnson; David A Vesey; Michael A McGuckin; Glenda C Gobe
Journal:  Cell Stress Chaperones       Date:  2017-09-27       Impact factor: 3.667

4.  Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.

Authors:  I H Chan; R Jain; M S Tessmer; D Gorman; R Mangadu; M Sathe; F Vives; C Moon; E Penaflor; S Turner; G Ayanoglu; C Chang; B Basham; J B Mumm; R H Pierce; J H Yearley; T K McClanahan; J H Phillips; D J Cua; E P Bowman; R A Kastelein; D LaFace
Journal:  Mucosal Immunol       Date:  2013-11-27       Impact factor: 7.313

5.  A regulatory polymorphism at position -309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression.

Authors:  Hyoungseok Ju; Byungho Lim; Minjin Kim; Yong Sung Kim; Woo Ho Kim; Chunhwa Ihm; Seung-Moo Noh; Dong Soo Han; Hang-Jong Yu; Bo Youl Choi; Changwon Kang
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 6.  Inflammation: a driving force speeds cancer metastasis.

Authors:  Yadi Wu; Binhua P Zhou
Journal:  Cell Cycle       Date:  2009-10-03       Impact factor: 4.534

7.  Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer.

Authors:  Stacey Meeker; Audrey Seamons; Jisun Paik; Piper M Treuting; Thea Brabb; William M Grady; Lillian Maggio-Price
Journal:  Cancer Res       Date:  2014-06-17       Impact factor: 12.701

Review 8.  Emerging tale of UPR and cancer: an essentiality for malignancy.

Authors:  Younis Mohammad Hazari; Arif Bashir; Ehtisham Ul Haq; Khalid Majid Fazili
Journal:  Tumour Biol       Date:  2016-09-14

9.  Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model.

Authors:  Debbie Liao; Yunping Luo; Dorothy Markowitz; Rong Xiang; Ralph A Reisfeld
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

Review 10.  Endotoxin and cancer.

Authors:  Jessica I Lundin; Harvey Checkoway
Journal:  Environ Health Perspect       Date:  2009-05-07       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.